
NRNVF
Healthcare · Biotechnology
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 27, 2020 | Time not confirmed | -1.79 | -1.87 | -4.5% |
| May 26, 2020 | Time not confirmed | -1.89 | -1.41 | +25.4% |
| Feb 27, 2020 | Time not confirmed | -1.69 | -2.16 | -27.8% |
| Nov 19, 2019 | Time not confirmed | -1.97 | -1.69 | +14.2% |
| Aug 22, 2019 | Time not confirmed | -1.68 | -2.02 | -20.2% |
| May 23, 2019 | Time not confirmed | -1.68 | -1.71 | -1.8% |
| Feb 27, 2019 | Time not confirmed | -2.17 | -1.78 | +18.0% |
| Nov 6, 2018 | Time not confirmed | -2.07 | -1.52 | +26.6% |
| Aug 22, 2018 | Time not confirmed | -2.08 | -1.68 | +19.2% |
| May 30, 2018 | Time not confirmed | -1.88 | -1.83 | +2.7% |
| Feb 27, 2018 | Time not confirmed | -1.78 | -1.73 | +2.8% |
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37…